Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial
A., Yu, O
& Saad, M
If youre intrigued by microdosing GLP-1 but not interested in extremes, explore clinician-guided GLP-1 care at AgelessRx to see what a lower-dose, long-term approach could look like for you.
Cognitive disorders Pre-clinical and mechanistic studies Our search retrieved a high number ( N = 189) of pre-clinical or mechanistic studies assessing the possible effects of GLP-1RAs on cognitive disorders, which cannot be described in the main text of this article due to space constraints (Supplementary Section 4)
When administering the lower dose of Semaglutide at 1 mg to treat patients with diabetes, the SUSTAIN study consistently demonstrated significant improvements in glucose control and body weight reduction 29,30,31,32,33,34,35